Statistical analyses were conducted with R software (version, 3.6.3) and Graph Prism (version, 9.0; GraphPad Software, Inc.; Dotmatics). The Wilcoxon rank sum test was used to compare the expression of RNF215 in CRC tumors with that in normal tissues. The Wilcoxon rank sum/Kruskal-Wallis test and logistic regression were performed to demonstrate the association between CRC clinicopathological characteristics and RNF215 expression. The CRC clinicopathological features correlated with survival were analyzed using the Kaplan-Meier method and Cox regression (23 (link)). Multivariate Cox analysis was conducted to assess the effect of RNF215 expression and the other clinicopathological features on survival. The variables with P<0.1 in univariate Cox regression analysis were further assessed in multivariate Cox regression analysis. Two-sided P-values <0.05 were considered to indicate a statistically significant difference.